Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Generic medicines

Delayed market entry for generic buprenorphine patches could have cost NHS £500,000, study concludes

Researchers calculated that if all generic low-dose transdermal buprenorphine patches were launched at the same time as Butec, there would have been a cost saving to the NHS of £1.2m, compared with savings of £0.7m from Butec entering the market alone.

Transdermal pain relief patch

Source: Science Photo Library

After the UK patent for BuTrans (pictured) expired, the delayed entry of multiple generic buprenorphine patches into the market potentially resulted in £500,000 worth of cost savings to the NHS being lost

Patent protection strategies that delayed the entry of multiple generic buprenorphine patches into the market in 2016 potentially resulted in £500,000 worth of savings being lost to the NHS, researchers have calculated.

In February 2016, the UK patent expired for the originator low-dose transdermal buprenorphine (LDTB) patch, BuTrans, which has been held by Napp Pharmaceuticals since 2005.

The company then launched Butec, an identical version of BuTrans that differed only in name and was priced at 15% less than the price of BuTrans.

At the same time, the generics manufacturer Sandoz obtained market authorisation to launch a generic LDTB patch (Reletrans).

However, Napp Pharmaceuticals claimed to the UK patents court that this was a breach of patent and the claim prevented the launch to market of all other generic LDTB patches for six months.

Researchers from schools of pharmacy at Keele University, Newcastle-under-Lyme, and Mosul in Iraq modelled two case scenarios, one where LDTB Butec entered the market alone between February 2016 and August 2016, and one where all generic LDTB patches entered the market at the same time.

They found that the introduction of all generic LDTB patches at the same time as Butec could have delivered a cost saving to the NHS of £1.2m, compared with £0.7m as a result of the entry of Butec alone.

“The entry of Butec was associated with cost savings,” the authors said. “[But] we estimated that more cost savings could have been achieved if other generic LDTB patches had entered the market at the same time to drive competition between rivals.”

However, the researchers highlighted that the approximate lost cost savings were much less than the potential savings lost from the prolongation of the patent of Lyrica (pregabalin), which have been estimated at approximately £500m.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206914

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.